BioCentury | Feb 24, 2017
Financial News

Lattice Biologics completes private placement

...On Feb. 16, cellular therapies and tissue engineering company Lattice Biologics Ltd. (TSX-V:LBL; OTCQB:LBLTF) raised C$131,652...
...shares, with each whole warrant exercisable at C$0.27. Lattice Biologics Ltd. (TSX-V:LBL; OTCQB:LBLTF), Scottsdale, Ariz. Alicia Parker Lattice...
BioCentury | Feb 3, 2017
Financial News

Lattice Biologics completes private placement

...Cellular therapies and tissue engineering company Lattice Biologics Ltd. (TSX-V:LBL) raised C$258,376 ($194,325) through the sale...
...C$0.27. The tranches closed on Jan. 24 & 26. Lattice Biologics Ltd. (TSX-V:LBL), Scottsdale, Ariz. Alicia Parker Lattice...
BioCentury | Oct 31, 2016
Financial News

Lattice Biologics completes private placement of units

...Raised: C$511,247 ($383,282) Units: 2.6 million Price: C$0.20 (unit) Shares after offering: 57.9 million Note: Lattice...
BioCentury | Aug 22, 2016
Financial News

Lattice Biologics completes private placement of units

...Raised: C$320,545 ($247,781) Units: 1.6 million Price: C$0.20 (unit) Shares after offering: 53 million Note: Lattice...
BioCentury | Jul 11, 2016
Financial News

Lattice Biologics completes private placement of units

...Raised: C$337,350 ($259,422) Units: 1.7 million Price: C$0.20 (unit) Shares after offering: 51.4 million Note: Lattice...
BioCentury | Apr 21, 2016
Targets & Mechanisms

Structural SERT-ainty

...Gouaux described as "a kind of molecular Velcro that helps the molecules form a crystal lattice."...
BioCentury | Jul 9, 2015
Product R&D

Downstream without a NET

ModiQuest B.V. has discovered that its therapeutic mAb against citrullinated histones has the potential to treat autoimmune diseases by inhibiting the formation of neutrophil extracellular traps that play a role in the pathogenesis of autoimmunity....
BioCentury | Apr 18, 2013
Tools & Techniques

Crystalline sponges to aid X-ray analysis

...were relatively simple and had a limited number of primary attachment points to the host lattice...
BioCentury | Jun 25, 2009
Strategy

Science for export

...tumor's sensitivity to a specific cancer drug 2005 Oxford, U.K. Not available Crysalin Ltd. Crysalin lattice...
BioCentury | Aug 30, 2004
Emerging Company Profile

Scancell: Apoptosis now

...Durrant said, "SC104 is a homophilic binding antibody that coats tumor cells in an antibody lattice...
Items per page:
1 - 10 of 13
BioCentury | Feb 24, 2017
Financial News

Lattice Biologics completes private placement

...On Feb. 16, cellular therapies and tissue engineering company Lattice Biologics Ltd. (TSX-V:LBL; OTCQB:LBLTF) raised C$131,652...
...shares, with each whole warrant exercisable at C$0.27. Lattice Biologics Ltd. (TSX-V:LBL; OTCQB:LBLTF), Scottsdale, Ariz. Alicia Parker Lattice...
BioCentury | Feb 3, 2017
Financial News

Lattice Biologics completes private placement

...Cellular therapies and tissue engineering company Lattice Biologics Ltd. (TSX-V:LBL) raised C$258,376 ($194,325) through the sale...
...C$0.27. The tranches closed on Jan. 24 & 26. Lattice Biologics Ltd. (TSX-V:LBL), Scottsdale, Ariz. Alicia Parker Lattice...
BioCentury | Oct 31, 2016
Financial News

Lattice Biologics completes private placement of units

...Raised: C$511,247 ($383,282) Units: 2.6 million Price: C$0.20 (unit) Shares after offering: 57.9 million Note: Lattice...
BioCentury | Aug 22, 2016
Financial News

Lattice Biologics completes private placement of units

...Raised: C$320,545 ($247,781) Units: 1.6 million Price: C$0.20 (unit) Shares after offering: 53 million Note: Lattice...
BioCentury | Jul 11, 2016
Financial News

Lattice Biologics completes private placement of units

...Raised: C$337,350 ($259,422) Units: 1.7 million Price: C$0.20 (unit) Shares after offering: 51.4 million Note: Lattice...
BioCentury | Apr 21, 2016
Targets & Mechanisms

Structural SERT-ainty

...Gouaux described as "a kind of molecular Velcro that helps the molecules form a crystal lattice."...
BioCentury | Jul 9, 2015
Product R&D

Downstream without a NET

ModiQuest B.V. has discovered that its therapeutic mAb against citrullinated histones has the potential to treat autoimmune diseases by inhibiting the formation of neutrophil extracellular traps that play a role in the pathogenesis of autoimmunity....
BioCentury | Apr 18, 2013
Tools & Techniques

Crystalline sponges to aid X-ray analysis

...were relatively simple and had a limited number of primary attachment points to the host lattice...
BioCentury | Jun 25, 2009
Strategy

Science for export

...tumor's sensitivity to a specific cancer drug 2005 Oxford, U.K. Not available Crysalin Ltd. Crysalin lattice...
BioCentury | Aug 30, 2004
Emerging Company Profile

Scancell: Apoptosis now

...Durrant said, "SC104 is a homophilic binding antibody that coats tumor cells in an antibody lattice...
Items per page:
1 - 10 of 13